Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial

Reuters01-12

Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial

Oncolytics Biotech Inc. announced updated clinical data from the GOBLET Cohort 4 study evaluating the combination of pelareorep and atezolizumab in patients with third-line metastatic squamous cell anal carcinoma (SCAC), a setting with no FDA-approved treatment options. The results, already presented, showed an objective response rate $(ORR)$ of approximately 29%, with two complete responses and two partial responses among 14 evaluable patients. The median duration of response (DOR) was approximately 17 months. These outcomes compare favorably to historical third-line SCAC studies, which report ORRs of around 10% or less. Oncolytics Biotech plans to meet with the FDA in Q1 2026 to discuss a potential registration strategy and the possibility of seeking accelerated approval for this indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623620) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602543221?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602543221","market":"nz","top_or_hot":-1,"title":"Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ONCWF\">Oncolytics Biotech Inc.</a> announced updated clinical data from the GOBLET Cohort 4 study evaluating the combination of pelareorep and atezolizumab in patients with third-line metastatic squamous cell anal carcinoma (SCAC), a setting with no FDA-approved treatment options. The results, already presented, showed an objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of approximately 29%, with two complete responses and two partial responses among 14 evaluable patients. The median duration of response (DOR) was approximately 17 months. These outcomes compare favorably to historical third-line SCAC studies, which report ORRs of around 10% or less. Oncolytics Biotech plans to meet with the FDA in Q1 2026 to discuss a potential registration strategy and the possibility of seeking accelerated approval for this indication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ONCY\">Oncolytics Biotech Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623620) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ONCWF\">Oncolytics Biotech Inc.</a> announced updated clinical data from the GOBLET Cohort 4 study evaluating the combination of pelareorep and atezolizumab in patients with third-line metastatic squamous cell anal carcinoma (SCAC), a setting with no FDA-approved treatment options. The results, already presented, showed an objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of approximately 29%, with two complete responses and two partial responses among 14 evaluable patients. The median duration of response (DOR) was approximately 17 months. These outcomes compare favorably to historical third-line SCAC studies, which report ORRs of around 10% or less. Oncolytics Biotech plans to meet with the FDA in Q1 2026 to discuss a potential registration strategy and the possibility of seeking accelerated approval for this indication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ONCY\">Oncolytics Biotech Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623620) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONCY","symbol_name":"Oncolytics Biotech Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbfTRHS:1","article_id":"2602543221","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602543221","pubTimestamp":1768226476,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Oncolytics Biotech Inc. announced updated clinical data from the GOBLET Cohort 4 study evaluating the combination of pelareorep and atezolizumab in patients with third-line metastatic squamous cell anal carcinoma , a setting with no FDA-approved treatment options. The results, already presented, showed an objective response rate  of approximately 29%, with two complete responses and two partial responses among 14 evaluable patients. The median duration of response  was approximately 17 months. These outcomes compare favorably to historical third-line SCAC studies, which report ORRs of around 10% or less. Oncolytics Biotech plans to meet with the FDA in Q1 2026 to discuss a potential registration strategy and the possibility of seeking accelerated approval for this indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONCY":"Oncolytics Biotech Inc","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4112":"金融交易所和数据","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Oncolytics Biotech报告Pelareorep联合Atezolizumab在三线肛门癌试验中的缓解率增加了两倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONCY":0.9,"NDAQ":0.9},"content_text":"Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial\n    \n\nOncolytics Biotech Inc. announced updated clinical data from the GOBLET Cohort 4 study evaluating the combination of pelareorep and atezolizumab in patients with third-line metastatic squamous cell anal carcinoma (SCAC), a setting with no FDA-approved treatment options. The results, already presented, showed an objective response rate $(ORR)$ of approximately 29%, with two complete responses and two partial responses among 14 evaluable patients. The median duration of response (DOR) was approximately 17 months. These outcomes compare favorably to historical third-line SCAC studies, which report ORRs of around 10% or less. Oncolytics Biotech plans to meet with the FDA in Q1 2026 to discuss a potential registration strategy and the possibility of seeking accelerated approval for this indication.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623620) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602543221","isCrawlerRequest":true}